{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:39:38Z","timestamp":1707525578523},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,10]]},"DOI":"10.7759\/cureus.52000","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T10:09:17Z","timestamp":1704881357000},"source":"Crossref","is-referenced-by-count":0,"title":["IgG4-Related Kidney Disease: A Diagnostic Conundrum Successfully Treated With Steroids and Rituximab"],"prefix":"10.7759","author":[{"given":"Anand","family":"Chellappan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Bhawane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratnesh","family":"Rokade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441005","article-title":"High serum IgG4 concentrations in patients with sclerosing pancreatitis","volume":"344","author":"Hamano H","year":"2001","unstructured":"Hamano H, Kawa S, Horiuchi A, et al.. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001, 344:732-8. 10.1056\/NEJM200103083441005","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta M","year":"2020","unstructured":"Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ. 2020, 369:m1067. 10.1136\/bmj.m1067","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01993-7","article-title":"Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version","volume":"25","author":"Saeki T","year":"2021","unstructured":"Saeki T, Kawano M, Nagasawa T, et al.. Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol. 2021, 25:99-109. 10.1007\/s10157-020-01993-7","journal-title":"Clin Exp Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1554321","article-title":"IgG4-related kidney disease and retroperitoneal fibrosis: an update","volume":"29","author":"Kawano M","year":"2019","unstructured":"Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: an update. Mod Rheumatol. 2019, 29:231-9. 10.1080\/14397595.2018.1554321","journal-title":"Mod Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi A","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, et al.. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015, 67:1688-99. 10.1002\/art.39132","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.191","article-title":"The clinical course of patients with IgG4-related kidney disease","volume":"84","author":"Saeki T","year":"2013","unstructured":"Saeki T, Kawano M, Mizushima I, et al.. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013, 84:826-33. 10.1038\/ki.2013.191","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-020-09163-3","article-title":"Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement","volume":"68","author":"Quattrocchio G","year":"2020","unstructured":"Quattrocchio G, Barreca A, Demarchi A, et al.. Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement. Immunol Res. 2020, 68:340-52. 10.1007\/s12026-020-09163-3","journal-title":"Immunol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers MN","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, et al.. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015, 74:1171-7. 10.1136\/annrheumdis-2014-206605","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.02.007","article-title":"Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease","volume":"15","author":"Culver EL","year":"2017","unstructured":"Culver EL, Sadler R, Bateman AC, et al.. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol. 2017, 15:1444-1452.e6. 10.1016\/j.cgh.2017.02.007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab","volume":"55","author":"Wallace ZS","year":"2016","unstructured":"Wallace ZS, Mattoo H, Mahajan VS, et al.. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016, 55:1000-8. 10.1093\/rheumatology\/kev438","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo M","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, et al.. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017, 12:e0183844. 10.1371\/journal.pone.0183844","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.12.029","article-title":"Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease","volume":"74","author":"Campochiaro C","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Lanzillotta M, et al.. Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease. Eur J Intern Med. 2020, 74:92-8. 10.1016\/j.ejim.2019.12.029","journal-title":"Eur J Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/218964-igg4-related-kidney-disease-a-diagnostic-conundrum-successfully-treated-with-steroids-and-rituximab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:13:20Z","timestamp":1707509600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/218964-igg4-related-kidney-disease-a-diagnostic-conundrum-successfully-treated-with-steroids-and-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.52000","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,10]]}}}